Results 131 to 140 of about 3,595 (167)

Trough levels of dalbavancin during long-term treatment of prosthetic joint infections

Infectious Diseases
Introduction Dalbavancin is a lipoglycopeptide with an exceptionally long half-life that allows simplified administration, which may be of value in long-term treatment of bone and joint infections, such as prosthetic joint infections (PJIs).
B. Söderquist, Max Möller, S. Salihovic   +2 more
semanticscholar   +1 more source

Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections.

Farmacia Hospitalaria
INTRODUCTION dalbavancin is approved for acute bacterial skin and soft tissue infections, but its off-label use in complex chronic infections has become increasingly common. Currently, no established dosing regimen exists for such infections.
L. Moñino-Domínguez, A. Aguado-Paredes, J. Cordero-Ramos   +2 more
semanticscholar   +1 more source

Gram-positive infections in special populations. Expert view on the role of dalbavancin

Expert Review of Anti-Infective Therapy
Introduction This review considers special populations as those patients for whom Gram-positive infections are particularly challenging to treat. We examine the potential benefits of dalbavancin in these patients.
Beatriz Sobrino, Sonia Luque, Eneritz Velasco-Arnaiz, Rubén Lovatti González, J. D. del Pozo   +4 more
semanticscholar   +1 more source

Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data

Entropy
This study investigates the use of Neural Ordinary Differential Equations (NODEs) as an alternative to traditional compartmental models and Nonlinear Mixed-Effects (NLME) models for drug concentration prediction in pharmacokinetics.
Tommaso Giacometti, E. Rocchi, Piergiogio Cojutti, Federico Magnani, D. Remondini, F. Pea, G. Castellani   +6 more
semanticscholar   +1 more source

Clinical, microbiological and laboratory predictors of on- and off-label dalbavancin treatment failure.

Journal of Global Antimicrobial Resistance
BACKGROUND Data about risk factors for treatment failure (TF) to dalbavancin are lacking. Our aim was to investigate the clinical, microbiological and laboratory predictors of TF in both on- and off-label dalbavancin treatments. METHODS We included all
M. Mazzitelli, D. Mengato, V. Scaglione, E. Giunco, Elena Barzizza, Luigi Salmaso, Francesca Venturini, A. Cattelan   +7 more
semanticscholar   +1 more source

Dalbavancin

Reactions Weekly, 2022
Michelle C. Simpson, Eric G. Schaefer
  +4 more sources

[Translated article] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections.

Farmacia Hospitalaria
INTRODUCTION dalbavancin is approved for treating acute bacterial skin and soft tissue infections, but its off-label use for treating complex chronic infections has become increasingly common.
L. Moñino-Domínguez, A. Aguado-Paredes, J. Cordero-Ramos   +2 more
semanticscholar   +1 more source

Dalbavancin (Xydalba)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Xydalba should be reimbursed by public drug plans for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA), only if certain conditions are met. Xydalba should only be covered to treat patients who have
openaire   +1 more source

Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections

Antimicrobial Agents and Chemotherapy
Here, we describe the use of proactive therapeutic drug monitoring (TDM) to individualize the optimal timing of drug injections in 16 adult patients with chronic osteoarticular infections receiving a median of 7 injections of dalbavancin (up to 12 ...
Dario Cattaneo, M. Fusi, Lucia Galli, C. Genovese, Riccardo Giorgi, Maddalena Matone, Stefania Merli, M. Colaneri, A. Gori   +8 more
semanticscholar   +1 more source

Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections

Global & Regional Health Technology Assessment
Introduction: Inpatient treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involves a significant economic burden on the healthcare system.
Matteo Scortichini, A. Ruggieri, A. Cattaneo, Patrizia Mascagni, P. Sciattella   +4 more
semanticscholar   +1 more source